CSIMarket
 


Ani Pharmaceuticals Inc  (ANIP)
Other Ticker:  
 
 

ANIP's Revenue Growth by Quarter and Year

Ani Pharmaceuticals Inc's Revenue results by quarter and year




ANIP Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 131.65 94.23 60.01 52.98
III Quarter September 131.83 83.82 48.63 48.47
II Quarter June 116.55 73.86 54.52 49.77
I Quarter March 106.79 64.48 57.25 47.97
FY   486.82 316.39 220.41 199.19



ANIP Revenue fourth quarter 2023 Y/Y Growth Comment
Ani Pharmaceuticals Inc reported Revenue improvement of 39.72% year on year in the fourth quarter 2023, to $ 131.65 millions, this is lower than Ani Pharmaceuticals Inc's recent average Revenue surge of 372.2%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Revenue growth. While Ani Pharmaceuticals Inc' s Revenue rise of 39.72% ranks overall at the positon no. 195 in the fourth quarter 2023.




ANIP Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 39.72 % 57.02 % 13.27 % 3.19 %
III Quarter September 57.28 % 72.36 % 0.33 % -10.84 %
II Quarter June 57.8 % 35.47 % 9.54 % -5.9 %
I Quarter March 65.62 % 12.63 % 19.35 % -16.02 %
FY   53.87 % 43.55 % 10.65 % -7.66 %

Financial Statements
Ani Pharmaceuticals Inc's fourth quarter 2023 Revenue $ 131.65 millions ANIP's Income Statement
Ani Pharmaceuticals Inc's fourth quarter 2022 Revenue $ 94.23 millions Quarterly ANIP's Income Statement
New: More ANIP's historic Revenue Growth >>


ANIP Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -0.13 % 12.42 % 23.4 % 9.3 %
III Quarter September 13.11 % 13.48 % -10.8 % -2.61 %
II Quarter June 9.14 % 14.55 % -4.77 % 3.75 %
I Quarter March 13.33 % 7.45 % 8.06 % -6.56 %
FY (Year on Year)   53.87 % 43.55 % 10.65 % -7.66 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #49
Overall #195

Revenue Y/Y Growth Statistics
High Average Low
6999.12 % 372.2 % -25.17 %
(Sep 30 2013)   (Dec 31 2015)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #30
Healthcare Sector #49
Overall #195
Revenue Y/Y Growth Statistics
High Average Low
6999.12 % 372.2 % -25.17 %
(Sep 30 2013)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Ani Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1682.5 % 53.35 % -22 %
(Dec 31 2012)  


ANIP's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Ani Pharmaceuticals Inc disclosed decrease in Revenue from the previous quarter by -0.13% to $ 131.65 millions, from $ 131.83 millions released in the previous reporting period.

Although seasonal factors usually energize IV. Quarter 2023 Revenue, that simply could not be sufficient to rescue Major Pharmaceutical Preparations's company achievement, Savannah T. Reed, an industry advisor from Boston pointed out and continued that average sequential Revenue growth is at 53.35% for ANIP.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Ani Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 1042.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #160
Overall #1042
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #160
Overall #1042
Revenue Q/Q Growth Statistics
High Average Low
1682.5 % 53.35 % -22 %
(Dec 31 2012)  


ANIP's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Ani Pharmaceuticals Inc reported decrease in Revenue from the previous quarter by -0.13% to $ 131.65 millions, from $ 131.83 millions declared in the previous reporting period.

Although cyclical factors usually energize IV. Quarter 2023 performance, it plainly could not be sufficient to rescue ANIP's IV. Quarter achievement, Savannah T. Reed, an industry advisor from Boston wrote.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Ani Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 1042.


Ani Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 486.82 $ 449.39 $ 401.39 $ 358.69 $ 316.39
Y / Y Revenue Growth (TTM) 53.87 % 59.27 % 62.53 % 57.57 % 43.54 %
Year on Year Revenue Growth Overall Ranking # 114 # 557 # 906 # 935 # 1386
Seqeuential Revenue Change (TTM) 8.33 % 11.96 % 11.9 % 13.37 % 12.13 %
Seq. Revenue Growth (TTM) Overall Ranking # 528 # 653 # 1296 # 1968 # 1825




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Ani Pharmaceuticals Inc's cumulative twelve months Revenue were $ 487 millions, company would post below average annual Revenue growth of 12.13% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Ani Pharmaceuticals Inc's Revenue growth from the 131.83% growth in Sep 30 2023.

Within the Healthcare sector 31 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 114, from total ranking in previous quarter at 557.

Revenue TTM Q/Q Growth Statistics
High Average Low
1491.6 %
90.09 %
-8.15 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 33
Healthcare Sector # 32
Overall # 114

Revenue TTM Y/Y Growth Statistics
High Average Low
1491.6 %
90.09 %
-8.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 92
S&P 500 # 528
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Ani Pharmaceuticals Inc's cumulative twelve months Revenue were $ 487 millions, company would post below average annual Revenue growth of -8.15% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Ani Pharmaceuticals Inc's Revenue growth from the 131.83% growth in Sep 30 2023.

Within the Healthcare sector 31 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 114, from total ranking in previous quarter at 557.

Revenue TTM Q/Q Growth Statistics
High Average Low
1491.6 %
90.09 %
-8.15 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 33
Healthcare Sector # 32
Overall # 114

Revenue TTM Y/Y Growth Statistics
High Average Low
1491.6 %
90.09 %
-8.15 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 92
S&P 500 # 528




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANIP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ANIP's Competitors
Revenue Growth for Ani Pharmaceuticals Inc's Suppliers
Revenue Growth for ANIP's Customers

You may also want to know
ANIP's Annual Growth Rates ANIP's Profitability Ratios ANIP's Asset Turnover Ratio ANIP's Dividend Growth
ANIP's Roe ANIP's Valuation Ratios ANIP's Financial Strength Ratios ANIP's Dividend Payout Ratio
ANIP's Roa ANIP's Inventory Turnover Ratio ANIP's Growth Rates ANIP's Dividend Comparisons



Companies with similar Revenue decrease for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Elite Pharmaceuticals Inc 68.64%$ 68.637 millions
Nephros Inc 67.97%$ 67.971 millions
Bicycle Therapeutics Plc67.38%$ 67.378 millions
Cyclo Therapeutics Inc 66.70%$ 66.699 millions
Beigene ltd 66.67%$ 66.666 millions
Agios Pharmaceuticals Inc 64.80%$ 64.803 millions
Lifemd Inc 64.28%$ 64.276 millions
Lumos Pharma Inc 61.33%$ 61.328 millions
Inspiremd Inc 58.66%$ 58.664 millions
Aurinia Pharmaceuticals Inc 58.59%$ 58.590 millions
Theralink Technologies Inc 51.82%$ 51.820 millions
Intra cellular Therapies Inc 50.34%$ 50.336 millions
Adma Biologics Inc 49.43%$ 49.427 millions
Insmed Inc48.27%$ 48.273 millions
Hims and Hers Health Inc 48.15%$ 48.151 millions
G1 Therapeutics Inc 45.10%$ 45.102 millions
Natera inc 43.20%$ 43.200 millions
Shockwave Medical Inc 41.36%$ 41.361 millions
Revance Therapeutics Inc 39.82%$ 39.819 millions
Evolus Inc 39.76%$ 39.759 millions
Ani Pharmaceuticals Inc39.71%$ 39.713 millions
Inspire Medical Systems inc 39.46%$ 39.459 millions
Insulet Corporation37.90%$ 37.896 millions
Foghorn Therapeutics Inc 37.88%$ 37.882 millions
Viemed Healthcare Inc 35.28%$ 35.275 millions
Kiniksa Pharmaceuticals ltd 34.76%$ 34.760 millions
Lantheus Holdings Inc 34.56%$ 34.557 millions
Xeris Biopharma Holdings Inc 33.93%$ 33.931 millions
Deciphera Pharmaceuticals Inc 32.88%$ 32.877 millions
Urogen Pharma Ltd 32.54%$ 32.539 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com